PTCT Live signaler | Maksimer profitt med Getagraph.com

KJøP 114402 min ago

@ $25.11

Utstedt: 14 feb 2024 @ 21:41

Avkastning: 31.46%

Forrige signal: feb 13 - 21:43

Forrige signal: Selg

Avkastning: 3.95 %

Live Chart Being Loaded With Signals

Commentary (3 mai 2024 @ 22:00):

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders...

Stats
Dagens volum	962 482
Gjennomsnittsvolum	911 217
Markedsverdi	2.53B
EPS	$0 ( 2024-04-25 )
Neste inntjeningsdato	( $-1.250 ) 2024-08-01
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-3.94
ATR14	$0.0370 (0.11%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-19	Klein Matthew B.	Sell	3 361	Common Stock
2024-04-17	Pauwels Eric	Sell	787	Common Stock
2024-04-17	Klein Matthew B.	Sell	1 307	Common Stock
2024-04-02	Golden Lee Scott	Sell	526	Common Stock
2024-02-15	Utter Christine Marie	Buy	2 900	Common Stock

INSIDER POWER
73.42
Last 98 transactions
Buy: 1 039 114 \| Sell: 204 439

Volum Korrelasjon

Lang: 0.20 (neutral)

Kort: 0.76 (moderate)

Signal:(53.36) Neutral

PTC Therapeutics Inc Korrelasjon

10 Mest positive korrelasjoner
MOSY	0.894
ATCX	0.831
IKNX	0.824
SPKE	0.821
ICON	0.82
SYKE	0.811
APOP	0.811
NTES	0.807
APR	0.805
UBX	0.804

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

PTC Therapeutics Inc Korrelasjon - Valuta/Råvare

0.53
( weak )

0.42
( neutral )

0.00
( neutral )

0.51
( weak )

0.27
( neutral )

-0.21
( neutral )

PTC Therapeutics Inc Økonomi

Annual	2023
Omsetning:	$937.82M
Bruttogevinst:	$649.70M (69.28 %)
EPS:	$-8.37

FY	2023
Omsetning:	$937.82M
Bruttogevinst:	$649.70M (69.28 %)
EPS:	$-8.37

FY	2022
Omsetning:	$698.80M
Bruttogevinst:	$654.12M (93.61 %)
EPS:	$-7.79

FY	2021
Omsetning:	$538.59M
Bruttogevinst:	$506.27M (94.00 %)
EPS:	$-7.26

Financial Reports:

No articles found.

PTC Therapeutics Inc

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.